Update on smallpox vaccines;Actualités sur la vaccination antivariolique

Medecine et Maladies Infectieuses

Volumn 34, Issue 1, 2004, Pages 20-27

  Garin, D ^a   Crance, J M ^a   Fuchs, F ^b   Autran, B ^c   Drillien, R ^d  

^a Laboratoire de Virologie   (France)

^b AFSSAPS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Bioterrorism; Smallpox; Vaccination; Vaccinia

Indexed keywords

SMALLPOX VACCINE;

BIOLOGICAL WARFARE; CATTLE; CELL CULTURE; ECZEMA; ENCEPHALITIS; ERYTHEMA; FRANCE; HUMAN; INFECTION; INJECTION SITE; NEEDLE; NONHUMAN; PAPULE; PERICARDITIS; POPULATION; REVIEW; SCAR FORMATION; SHEEP; SIDE EFFECT; SMALLPOX; SMALLPOX VIRUS; STEVENS JOHNSON SYNDROME; VIRUS STRAIN;

EID: 1642533704     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medmal.2003.09.007     Document Type: Short Survey

References (39)

1. Bazin H. Eradication of smallpox, already 20 years ago. Bull. Acad. Natl. Med. 184:(1):2000;89-99. discussion 99-104.
2. Henderson D.A. Weapons for the future. Lancet. 354:(Suppl):1999;SIV64.
3. Crance J.M., Lamarque D., Scaramozzino N., Ferrier-Rembert A., Agay D., Garin D. Variole : la menace fantôme. Médecine et armées. 30:(5):2002;495-502.
4. Lane J.M. Hazards of smallpox vaccination. Jama. 247:(19):1982;2709.
5. Alibek K. The Soviet Union's anti-agricultural biological weapons. Ann. N. Y. Acad. Sci. 894:1999;18-19.
6. Orent W. Escape from Moscow. The sciences. 3:1998;26-31.
7. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:(3):2001;1205-1210.
8. Cavallo A.P. Participation du service de santé des armées à une campagne d'éradication de la variole en Somalie. Médecine et armées. 14:(8):1986;671-675.
9. Smallpox eradication: destruction of variola virus stocks. Wkly Epidemiol. Rec. 77:(5):2002;34-38.
10. WHO. Smallpox vaccine. Report. WHO technical report series 1966; 323: 7-11.
11. Note for guidance on the development of vaccinia virus based vaccines against smallpox. EMEA report. 2002;1-19.
12. Rosenthal S.R., Merchlinsky M., Kleppinger C., Goldenthal K.L. Developing new smallpox vaccines. Emerg. Infect. Dis. 7:(6):2001;920-926.
13. Dyer O. UK smallpox vaccine comes under fire from US. British Medical Journal. 325:(7359):2002;298.
14. Galmiche M.C., Goenaga J., Wittek R., Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology. 254:(1):1999;71-80.
15. Hooper J.W., Custer D.M., Schmaljohn C.S., Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 266:(2):2000;329-339.
16. Hooper J.W., Custer D.M., Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 306:(1):2003;181-195.
17. Sugimoto M., Yasuda A., Miki K., Morita M., Suzuki K., Uchida N., et al. Gene structures of low-xneurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains. Microbiol. Immunol. 29:(5):1985;421-428.
18. Takahashi-Nishimaki F., Suzuki K., Morita M., Maruyama T., Miki K., Hashizume S., et al. Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination. J. Gen. Virol. 68:(Pt 10):1987;2705-2710.
19. Mahnel H., Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl. Munch. Tierarztl. Wochenschr. 107:(8):1994;253-256.
20. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 188:(1):1992;217-232.
21. Ober B.T., Bruhl P., Schmidt M., Wieser V., Gritschenberger W., Coulibaly S., et al. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J. Virol. 76:(15):2002;7713-7723.
22. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:(1):2000;10-19.
23. Bartlett J., Borio L., Radonovich L., Mair J.S., O'Toole T., Mair M., et al. Smallpox vaccination in 2003: key information for clinicians. Clin. Infect. Dis. 36:2003;883-902.
24. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122:(4):1970;303-309.
25. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281:(22):1969;1201-1208.
26. Henderson D.A. Principles and lessons from the smallpox eradication programme. Bull. World Health Organ. 65:(4):1987;535-546.
27. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication. 1988;WHO, Geneva.
28. Neff J.M., Lane J.M., Pert J.H., Moore R., Millar J.D., Henderson D.A. Complications of smallpox vaccination. I. National survey in the United States, 1963. N. Engl. J. Med. 276:(3):1967;125-132.
29. Nanning W. Prophylactic effect of antivaccinia gammaglogulin against post-vaccinal encephalitis. Bull. World Health Organ. 27:1962;317-324.
30. Sharp J.C., Fletcher W.B. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet. 1:(7804):1973;656-659.
31. Feery B.J. The efficacy of vaccinial immune globulin. A 15-year study. Vox Sang. 31:(1 SUPPL):1976;68-76.
32. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP), 2001. MMWR Recomm. Rep. 50:(RR-10):2001;1-25.
33. Klietmann W.F., Ruoff K.L. Bioterrorism: implications for the clinical microbiologist. Clin. Microbiol. Rev. 14:(2):2001;364-381.
34. Drazen J.M. Smallpox and biorerrorism. N. Engl. J. Med. 346:(17):2002;1262-1263.
35. Grabenstein J.D., Winkenwerder W. Jr. US military smallpox vaccination program experience. Jama. 289:(24):2003;3278-3282.
36. Update: cardiac and other adverse events following civilian smallpox vaccination. United States, 2003. MMWR Morb. Mortal Wkly Rep. 52:(27):2003;639-642.
37. Women with smallpox vaccine exposure during pregnancy reported to the national smallpox vaccine in pregnancy reigistry. United states, 2003. MMWR Morb. Mortal Wkly Rep. 52:(17):2003;386-388.
38. Halsell J.S., Riddle J.R., Atwood J.E., Gardner P., Shope R., Poland G.A., et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. Jama. 289:(24):2003;3283-3289.
39. Update; adverse events following civilian smallpox vaccination. United States, 2003. MMWR Morb. Mortal Wkly Rep. 52:(13):2003;278-282.